公开(公告)号：US20210102957A1

公开(公告)日：2021-04-08

申请号：US17069272

申请日：2020-10-13

Applicant: bioAffinity Technologies, Inc.

Inventor： Vivienne I. Rebel

IPC: G01N33/68

Abstract: Predicting the likelihood of lung disease in a subject, comprising labeling an ex-vivo sputum sample from a subject with one or more of the following: a first labeled probe that binds a biomarker expressed on a white blood cell population in the sample; a second labeled probe selected from the group consisting of: a granulocyte probe, a T-cell probe, a B-cell probe, or any combination thereof; a third labeled probe that binds a biomarker on a macrophage cell population; a fourth labeled probe that binds to a disease related cell in the sample; a fifth labeled probe that binds to a biomarker expressed on an epithelial cell population; and a sixth labeled probe that binds to a cell surface biomarker expressed on an epithelial cell population to obtain data comprising a mean fluorescent signature and detecting a profile based upon a presence or absence of labeled probes.

公开(公告)号：US20150160197A1

公开(公告)日：2015-06-11

申请号：US14532998

申请日：2014-11-04

Applicant: bioAffinity Technologies, Inc.

Inventor： Constance Dorian ,  John Cousins ,  Gordon Bennett

IPC: G01N33/50 ,  G01N21/64

CPC classification number: G01N33/5091 ,  G01N21/6428 ,  G01N33/52 ,  G01N33/57423 ,  G01N33/57492 ,  G01N33/582 ,  G01N2021/6439 ,  G01N2458/30 ,  G01N2800/12

Abstract: One embodiment of the present invention provides for a method of determining if a sputum sample contains dysplastic or carcinomic cells by obtaining a sputum sample containing cells. The sputum sample is labeled with TCPP to stain cells suspected to be dysplastic or carcinomic. The labeled sputum sample is excited with an excitation wavelength of light of about 475 nm +/−30 nm and emission at about 560 nm +/−30 nm is detected from cells identified to be macrophages. An imager focuses on the plasma membrane of one or more cells suspected to be dysplastic or carcinomic and emission at about 655 nm +/−30 nm, if present, is detected for TCPP labeled cells of the sputum sample after focusing on the plasma membrane of the cells of the sputum sample. Photon flux for each pixel of a sensor is measured to obtain a value for the imaged cell. The measured value is scored to determine if a cell is cancerous or dysplastic.

Abstract translation: 本发明的一个实施方案提供了通过获得含有细胞的痰样品来确定痰样品是否含有发育不良或癌细胞的方法。 痰样品用TCPP标记，以染色疑似发育不良或致癌的细胞。 标记的痰样品用约475nm±30nm的光的激发波长激发，并且从鉴定为巨噬细胞的细胞中检测到在约560nm±30nm的发射。 成像仪专注于一个或多个怀疑是发育异常或致癌的细胞的质膜，并且在聚焦于痰样品的质膜上的痰样品的TCPP标记细胞上检测到约655nm±30nm（如果存在）的发射 痰样品的细胞。 测量传感器每个像素的光子通量以获得成像单元的值。 评估测量值以确定细胞是否是癌性或发育异常。

公开(公告)号：US20240302360A1

公开(公告)日：2024-09-12

申请号：US18667900

申请日：2024-05-17

Applicant: BIOAFFINITY TECHNOLOGIES, INC.

Inventor： William E. Bauta

IPC: G01N33/533 ,  G01N33/547

CPC classification number: G01N33/533 ,  G01N33/547

Abstract: A compensation bead comprising an amine functionalized bead modified covalently or non-covalently with a carboxyaryl porphyrin, a method for making the amine functionalized bead with the carboxyaryl porphyrin and a method of using the amine functionalized bead with the carboxyaryl porphyrin as a marker for the carboxyaryl porphyrin labeled cells and particles.

公开(公告)号：US20230035774A1

公开(公告)日：2023-02-02

申请号：US17359905

申请日：2021-06-28

Applicant: bioAffinity Technologies, Inc.

Inventor： David J. Elzi ,  William E. Bauta ,  Vivienne I. Rebel

IPC: C12N15/113

Abstract: A double stranded RNA interference (RNAi) agent comprising at least one of (i) a first double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a CD320 gene wherein the first dsRNA comprises a sense strand and an antisense strand forming a duplex, (ii) a second dsRNA for inhibiting the expression of a LRP2 gene wherein the second dsRNA comprises a sense strand and an antisense strand forming a duplex, or (iii) a cocktail of (i) and (ii) and wherein the sense strand of the first dsRNA is at least substantially complementary to the antisense strand of the first dsRNA and the sense strand of the second dsRNA is at least substantially complementary to the antisense strand of the second dsRNA and the use of the RNAi agent as a pharmaceutical composition for the treatment of cancer in subjects in need of treatment.

公开(公告)号：US20250069747A1

公开(公告)日：2025-02-27

申请号：US18745375

申请日：2024-06-17

Applicant: bioAffinity Technologies, Inc.

Inventor： Vivienne I. Rebel ,  Madeleine E. Lemieux

IPC: G16H50/20 ,  A61B10/00 ,  G01N15/14 ,  G01N15/1429 ,  G16B40/20

Abstract: A system and method for analyzing a sputum sample from a subject suspected of having lung cancer comprising obtaining a plurality of cells from the sputum sample from the subject, marking the plurality of cells with i) a plurality of cell lineage specific marker compositions, ii) a cell viability composition and iii) a tetra (4-carboxyphenyl) porphyrin (TCPP) composition; analyzing with the flow cytometer the plurality of cells marked with i-iii to obtain a subpopulation selected for cell size from the plurality of cells based upon an automatically selected bead size exclusion gate; from the cell size selected subpopulation, selecting a viable singlet population of cells using an automated non-debris gate and an automated singlets gate; from the viable singlet population of cells, obtaining flow cytometer values based upon the plurality of cell lineage specific marker compositions, the viability marker and the TCPP marker; applying a trained classifier to meta data from the subject and the flow cytometric values obtained; and generating, based upon the application of the trained classifier, a classification for the sputum sample wherein the classification is selected from a plurality of classification options comprising cancer and non-cancer.

公开(公告)号：US09417241B2

公开(公告)日：2016-08-16

申请号：US14643194

申请日：2015-03-10

Applicant: bioAffinity Technologies, Inc.

Inventor： Jeffrey Garwin

IPC: A61K31/409 ,  G01N33/574 ,  G01N33/50 ,  G01N33/52

CPC classification number: G01N33/574 ,  A61K31/409 ,  G01N33/5091 ,  G01N33/52

Abstract: Presented is a kit containing TCPP for use in prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

Abstract translation: 提出了一种包含TCPP的试剂盒，用于预测患者对癌症治疗的反应，其中在治疗之前，用来自患者的组织或被治疗癌症的器官的细胞样品与TCPP的溶液接触以允许TCPP与 异常发育不良或癌细胞的组分（如有）; 检测样品中的TCPP荧光，TCPP荧光的存在表明样品含有发育异常或癌细胞; 在治疗期间以及在治疗后对来自患者被治疗癌症的组织或器官的另一个细胞样品进行a-c的治疗后， 并且确定在治疗期间和之后测试的样品中异常的前癌细胞的百分比是否与在治疗之前测试的样品相比减少，所述减少是患者对癌症治疗的反应的预后。

公开(公告)号：US20150177245A1

公开(公告)日：2015-06-25

申请号：US14643194

申请日：2015-03-10

Applicant: bioAffinity Technologies, Inc.

Inventor： Jeffrey Garwin

IPC: G01N33/574

CPC classification number: G01N33/574 ,  A61K31/409 ,  G01N33/5091 ,  G01N33/52

Abstract: Presented is a method of prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

Abstract translation: 提出了一种预测患者对癌症治疗的反应的方法，其中在治疗之前接触来自患者的组织或被治疗癌症的器官的细胞样品与TCPP的溶液接触以允许TCPP与异常组分的结合 发育不良或癌细胞（如有）; 检测样品中的TCPP荧光，TCPP荧光的存在表明样品含有发育异常或癌细胞; 在治疗期间以及在治疗后对来自患者被治疗癌症的组织或器官的另一个细胞样品进行a-c的治疗后， 并且确定在治疗期间和之后测试的样品中异常的前癌细胞的百分比是否与在治疗之前测试的样品相比减少，所述减少是患者对癌症治疗的反应的预后。